NCT05646836View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Cevostamab

Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.

DRUG

XmAb24306

XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.

DRUG

Tocilizumab

Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Trial Locations (13)

3000

Peter Maccallum Cancer Centre, Melbourne

3004

Alfred Hospital, Melbourne

5000

Royal Adelaide Hospital, Adelaide

7100

Sygehus Lillebaelt - Vejle Sygehus, Vejle

31008

Clinica Universidad de Navarra, Pamplona

46026

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

64239

Tel Aviv Sourasky Medical Center PPDS, Tel Aviv

4941492

Rabin Medical Center-Beilinson Campus, Petah Tikva

106 76

Evangelismos General Hospital of Athens, Athens

115 28

University of Athens, Hematological Clinic,, Athens

N - 0424

Oslo University Hospital Rikshospitalet, Oslo

03722

Severance Hospital, Yonsei University, Seoul

05505

Asan Medical Center - PPDS, Seoul

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT05646836 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter